APROGEN MEDICINES INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,315 KRW | -2.66% |
|
-11.15% | +36.98% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 716,820 | 417,454 | 374,121 | 335,573 | 399,707 | 234,315 |
| Enterprise Value (EV) 1 | 776,100 | 327,544 | 222,313 | 254,743 | 442,443 | 318,048 |
| P/E ratio | -12.3 x | -34.4 x | -7.46 x | -18.1 x | -3.45 x | -4.07 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 14 x | 5.33 x | 2.94 x | 2.38 x | 5.1 x | 1.56 x |
| EV / Revenue | 15.2 x | 4.19 x | 1.75 x | 1.8 x | 5.65 x | 2.11 x |
| EV / EBITDA | 222 x | 81.4 x | 31.1 x | -395 x | -5 x | -4.83 x |
| EV / FCF | -133 x | -2.52 x | -4.57 x | -1.98 x | -3.05 x | -14.7 x |
| FCF Yield | -0.75% | -39.6% | -21.9% | -50.6% | -32.8% | -6.81% |
| Price to Book | 3.67 x | 1.55 x | 1.17 x | 1 x | 1.86 x | 1.59 x |
| Nbr of stocks (in thousands) | 30,633 | 51,065 | 60,981 | 66,384 | 232,930 | 244,079 |
| Reference price 2 | 23,400 | 8,175 | 6,135 | 5,055 | 1,716 | 960.0 |
| Announcement Date | 3/21/19 | 3/13/20 | 3/19/21 | 3/23/22 | 3/27/23 | 3/19/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 51,047 | 78,249 | 127,143 | 141,247 | 78,349 | 150,578 |
| EBITDA 1 | 3,502 | 4,026 | 7,152 | -644.7 | -88,552 | -65,899 |
| EBIT 1 | 1,469 | 775.1 | 2,844 | -4,902 | -116,944 | -94,970 |
| Operating Margin | 2.88% | 0.99% | 2.24% | -3.47% | -149.26% | -63.07% |
| Earnings before Tax (EBT) 1 | -22,005 | 16,923 | -39,117 | -9,182 | -115,611 | -95,239 |
| Net income 1 | -32,108 | -10,839 | -46,490 | -18,002 | -98,657 | -55,619 |
| Net margin | -62.9% | -13.85% | -36.57% | -12.75% | -125.92% | -36.94% |
| EPS 2 | -1,895 | -237.8 | -822.2 | -279.6 | -497.4 | -236.0 |
| Free Cash Flow 1 | -5,820 | -129,818 | -48,660 | -128,980 | -145,213 | -21,656 |
| FCF margin | -11.4% | -165.9% | -38.27% | -91.31% | -185.34% | -14.38% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/21/19 | 3/13/20 | 3/19/21 | 3/23/22 | 3/27/23 | 3/19/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 59,280 | - | - | - | 42,736 | 83,732 |
| Net Cash position 1 | - | 89,910 | 151,809 | 80,830 | - | - |
| Leverage (Debt/EBITDA) | 16.93 x | - | - | - | -0.4826 x | -1.271 x |
| Free Cash Flow 1 | -5,820 | -129,818 | -48,660 | -128,980 | -145,213 | -21,656 |
| ROE (net income / shareholders' equity) | -14.4% | 5.14% | -5.41% | -1.79% | -50.5% | -22.1% |
| ROA (Net income/ Total Assets) | 0.28% | 0.09% | 0.24% | -0.37% | -13.6% | -9.94% |
| Assets 1 | -11,583,058 | -11,667,242 | -19,378,881 | 4,872,019 | 727,208 | 559,551 |
| Book Value Per Share 2 | 6,382 | 5,262 | 5,232 | 5,061 | 923.0 | 606.0 |
| Cash Flow per Share 2 | 1,956 | 1,399 | 1,584 | 940.0 | 185.0 | 146.0 |
| Capex 1 | 4,036 | 7,853 | 2,576 | 1,380 | 19,610 | 25,514 |
| Capex / Sales | 7.91% | 10.04% | 2.03% | 0.98% | 25.03% | 16.94% |
| Announcement Date | 3/21/19 | 3/13/20 | 3/19/21 | 3/23/22 | 3/27/23 | 3/19/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +36.98% | 241M | |
| +19.00% | 6.43B | |
| -0.48% | 3.07B | |
| -1.12% | 2.9B | |
| -17.13% | 1.55B | |
| -2.36% | 1.06B | |
| -30.58% | 929M | |
| +3.66% | 707M | |
| -33.20% | 663M | |
| +7.85% | 554M |
- Stock Market
- Equities
- A007460 Stock
- Financials Aprogen Medicines Inc.
